Clinical Trial Detail

NCT ID NCT02460991
Title A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors CeloNova BioSciences, Inc.
Indications

hepatocellular carcinoma

Therapies

Sorafenib

Doxorubicin

Age Groups: adult

No variant requirements are available.